Liping Wu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Liping Wu has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
Xiaobin Sun
Department of Gastroenterology, The Affiliated Hospital of Southwest Jiao Tong University, The Third People’s Hospital of Chengdu, Chengdu, China
7 shared publicationsYumei He
North Sichuan Medical College, Nanchong, China
7 shared publicationsLu Li
Department of Gastroenterology, the Affiliated Hospital of Southwest Medical University, Luzhou 646000, Sichuan, China
6 shared publicationsShiyan Wu
Department of Gastroenterology, the Affiliated Hospital of Southwest Medical University, Luzhou 646000, Sichuan, China
6 shared publicationsZhiming Wang
Department of Gastroenterology, The Third People's Hospital of Chengdu, Chengdu 610031, Sichuan, China
5 shared publications- Chao Sun
Department of Gastroenterology, The First Affiliated Hospital of Xi'an Medical University, Xi'an, Shaanxi 710077, China
4 shared publications
Latest Publications
- 20 January 2026
- Published by Elsevier in International Immunopharmacology
- Vol. 172, 116252
Silencing PAR-2 in macrophages promotes PANoptosis and triggers duodenal microinflammation in functional dyspepsia
- 20 January 2026
- Published by Elsevier in International Immunopharmacology
- Vol. 172, 116252
Silencing PAR-2 in macrophages promotes PANoptosis and triggers duodenal microinflammation in functional dyspepsia
- Open Access
- 19 June 2025
- Published by Frontiers Media SA in Frontiers in Nutrition
- Vol. 12, 1612417
The global leadership initiative on malnutrition criteria for the diagnosis of malnutrition in patients with chronic liver diseases: a systematic review and meta-analysis
Background: Malnutrition in patients with chronic liver disease (CLD) is linked to increased mortality and a high risk of morbidity. Assessing the nutritional status of patients with CLD is challenging. The Global Leadership Initiative for Malnutrition (GLIM) offers a novel diagnostic framework for malnutrition. However, the efficacy of GLIM in CLD patients has not been validated.Methods: A systematic review and meta-analysis were conducted to evaluate the utility and diagnostic accuracy of the GLIM criteria in adult patients with CLD, involving a search of seven databases for relevant studies. The evaluation of quality was conducted with the QUADAS-2 tool.Results: The analysis included a total of five studies. Sample size ranged from 109 to 406 among different studies. According to the GLIM criteria, around 21.2 to 69.9% of individuals were identified as having malnutrition. Simultaneously, the subjective global assessment (SGA) detected malnourished patients ranging from 35.0 to 86.0%. Five studies compared the GLIM with the SGA. The nutritional assessment process in the studies was not clear according to the QUADAS-2 tool. The overall specificity of the meta-analysis was 85.8% (95% CI: 82.5–88.7%) and the overall sensitivity was 49.1% (95% CI: 45.5–52.8%).Conclusion: This is the first systematic review and meta-analysis on GLIM criteria, SGA and CLD patients. The applicability and reliability of the GLIM criteria in CLD patients remain constrained. Furthermore, certain validation studies that are parallel and predictive may have methodological limitations. Additional research is needed to confirm the applicability of the GLIM criteria in patients with CLD.Systematic review registration: PROSPERO, CRD420251010347.
- 19 June 2025
- Published by Frontiers Media SA in Frontiers in Nutrition
- Vol. 12, 1612417
Open AccessThe global leadership initiative on malnutrition criteria for the diagnosis of malnutrition in patients with chronic liver diseases: a systematic review and meta-analysis
Background: Malnutrition in patients with chronic liver disease (CLD) is linked to increased mortality and a high risk of morbidity. Assessing the nutritional status of patients with CLD is challenging. The Global Leadership Initiative for Malnutrition (GLIM) offers a novel diagnostic framework for malnutrition. However, the efficacy of GLIM in CLD patients has not been validated.Methods: A systematic review and meta-analysis were conducted to evaluate the utility and diagnostic accuracy of the GLIM criteria in adult patients with CLD, involving a search of seven databases for relevant studies. The evaluation of quality was conducted with the QUADAS-2 tool.Results: The analysis included a total of five studies. Sample size ranged from 109 to 406 among different studies. According to the GLIM criteria, around 21.2 to 69.9% of individuals were identified as having malnutrition. Simultaneously, the subjective global assessment (SGA) detected malnourished patients ranging from 35.0 to 86.0%. Five studies compared the GLIM with the SGA. The nutritional assessment process in the studies was not clear according to the QUADAS-2 tool. The overall specificity of the meta-analysis was 85.8% (95% CI: 82.5–88.7%) and the overall sensitivity was 49.1% (95% CI: 45.5–52.8%).Conclusion: This is the first systematic review and meta-analysis on GLIM criteria, SGA and CLD patients. The applicability and reliability of the GLIM criteria in CLD patients remain constrained. Furthermore, certain validation studies that are parallel and predictive may have methodological limitations. Additional research is needed to confirm the applicability of the GLIM criteria in patients with CLD.Systematic review registration: PROSPERO, CRD420251010347.
- Open Access
- 1 January 2025
- Published by SAGE Publications in Science Progress
- Vol. 108 (1)
Development and external validation of Global Leadership Initiative on Malnutrition-dictated nomograms predicting long-term mortality in hospitalized patients with cirrhosis
Objectives: Global Leadership Initiative on Malnutrition (GLIM) criteria have gradually accounted for the mainstay evaluating nutritional status. We sought to establish GLIM-dictated nomograms with other prognostic factors influencing long-term mortality and externally validate their predictive performance in decompensated cirrhosis. Methods: The derivation cohort comprised 301 patients presenting with cirrhosis-associated acute insults, while the validation cohort encompassed 101 subjects from another tertiary hospital. Two nomograms were constructed to predict the 1-year all-cause mortality by integrating the GLIM criteria. The study population was stratified into low-, moderate- and high-risk mortality groups according to aforesaid proposed models. Results: Adjusting Child-Turcotte-Pugh classification (Nomo#1) or Model for End-stage Liver Disease-Sodium score (Nomo#2) separately, the GLIM criteria were independently associated with 1-year mortality in the multivariate Cox regression analysis (Nomo#1 hazard ratio (HR) = 3.139, p < 0.001; Nomo#2 HR = 3.456, p < 0.001). The C-index and time AUC for Nomo#1 and Nomo#2 performed significantly better than those of the GLIM criteria or conventional scoring systems alone. The survival rate of the low-risk group was significantly higher than those of the moderate- or high-risk groups (Nomo#1: 95% vs 65.8% vs 33.3%, p < 0.001; Nomo#2: 94.3% vs 64.5% vs 25%, p < 0.001). Furthermore, our proposed models exhibited moderate prediction accuracy and may identify malnourished patients with poor survival conditions in the external validation cohort. Conclusion: GLIM criteria-defined malnutrition negatively impacted long-term mortality in the context of decompensated cirrhosis. Our established nomograms may predict survival status with sufficient discriminatory ability, alongside good consistency and clinical benefits, supporting their effectiveness in daily practice.
- 1 January 2025
- Published by SAGE Publications in Science Progress
- Vol. 108 (1)
Open AccessDevelopment and external validation of Global Leadership Initiative on Malnutrition-dictated nomograms predicting long-term mortality in hospitalized patients with cirrhosis
Objectives: Global Leadership Initiative on Malnutrition (GLIM) criteria have gradually accounted for the mainstay evaluating nutritional status. We sought to establish GLIM-dictated nomograms with other prognostic factors influencing long-term mortality and externally validate their predictive performance in decompensated cirrhosis. Methods: The derivation cohort comprised 301 patients presenting with cirrhosis-associated acute insults, while the validation cohort encompassed 101 subjects from another tertiary hospital. Two nomograms were constructed to predict the 1-year all-cause mortality by integrating the GLIM criteria. The study population was stratified into low-, moderate- and high-risk mortality groups according to aforesaid proposed models. Results: Adjusting Child-Turcotte-Pugh classification (Nomo#1) or Model for End-stage Liver Disease-Sodium score (Nomo#2) separately, the GLIM criteria were independently associated with 1-year mortality in the multivariate Cox regression analysis (Nomo#1 hazard ratio (HR) = 3.139, p < 0.001; Nomo#2 HR = 3.456, p < 0.001). The C-index and time AUC for Nomo#1 and Nomo#2 performed significantly better than those of the GLIM criteria or conventional scoring systems alone. The survival rate of the low-risk group was significantly higher than those of the moderate- or high-risk groups (Nomo#1: 95% vs 65.8% vs 33.3%, p < 0.001; Nomo#2: 94.3% vs 64.5% vs 25%, p < 0.001). Furthermore, our proposed models exhibited moderate prediction accuracy and may identify malnourished patients with poor survival conditions in the external validation cohort. Conclusion: GLIM criteria-defined malnutrition negatively impacted long-term mortality in the context of decompensated cirrhosis. Our established nomograms may predict survival status with sufficient discriminatory ability, alongside good consistency and clinical benefits, supporting their effectiveness in daily practice.
- Open Access
- 23 September 2024
- Published by Oxford University Press (OUP) in Briefings in Bioinformatics
- Vol. 25 (6)
Development and validation of an explainable machine learning model for predicting multidimensional frailty in hospitalized patients with cirrhosis
We sought to develop and validate a machine learning (ML) model for predicting multidimensional frailty based on clinical and laboratory data. Moreover, an explainable ML model utilizing SHapley Additive exPlanations (SHAP) was constructed. This study enrolled 622 patients hospitalized due to decompensating episodes at a tertiary hospital. The cohort data were randomly divided into training and test sets. External validation was carried out using 131 patients from other tertiary hospitals. The frail phenotype was defined according to a self-reported questionnaire (Frailty Index). The area under the receiver operating characteristics curve was adopted to compare the performance of five ML models. The importance of the features and interpretation of the ML models were determined using the SHAP method. The proportions of cirrhotic patients with nonfrail and frail phenotypes in combined training and test sets were 87.8% and 12.2%, respectively, while they were 88.5% and 11.5% in the external validation dataset. Five ML algorithms were used, and the random forest (RF) model exhibited substantially predictive performance. Regarding the external validation, the RF algorithm outperformed other ML models. Moreover, the SHAP method demonstrated that neutrophil-to-lymphocyte ratio, age, lymphocyte-to-monocyte ratio, ascites, and albumin served as the most important predictors for frailty. At the patient level, the SHAP force plot and decision plot exhibited a clinically meaningful explanation of the RF algorithm. We constructed an ML model (RF) providing accurate prediction of frail phenotype in decompensated cirrhosis. The explainability and generalizability may foster clinicians to understand contributors to this physiologically vulnerable situation and tailor interventions.
- 23 September 2024
- Published by Oxford University Press (OUP) in Briefings in Bioinformatics
- Vol. 25 (6)
Open AccessDevelopment and validation of an explainable machine learning model for predicting multidimensional frailty in hospitalized patients with cirrhosis
We sought to develop and validate a machine learning (ML) model for predicting multidimensional frailty based on clinical and laboratory data. Moreover, an explainable ML model utilizing SHapley Additive exPlanations (SHAP) was constructed. This study enrolled 622 patients hospitalized due to decompensating episodes at a tertiary hospital. The cohort data were randomly divided into training and test sets. External validation was carried out using 131 patients from other tertiary hospitals. The frail phenotype was defined according to a self-reported questionnaire (Frailty Index). The area under the receiver operating characteristics curve was adopted to compare the performance of five ML models. The importance of the features and interpretation of the ML models were determined using the SHAP method. The proportions of cirrhotic patients with nonfrail and frail phenotypes in combined training and test sets were 87.8% and 12.2%, respectively, while they were 88.5% and 11.5% in the external validation dataset. Five ML algorithms were used, and the random forest (RF) model exhibited substantially predictive performance. Regarding the external validation, the RF algorithm outperformed other ML models. Moreover, the SHAP method demonstrated that neutrophil-to-lymphocyte ratio, age, lymphocyte-to-monocyte ratio, ascites, and albumin served as the most important predictors for frailty. At the patient level, the SHAP force plot and decision plot exhibited a clinically meaningful explanation of the RF algorithm. We constructed an ML model (RF) providing accurate prediction of frail phenotype in decompensated cirrhosis. The explainability and generalizability may foster clinicians to understand contributors to this physiologically vulnerable situation and tailor interventions.
- Open Access
- 18 July 2024
- Published by Frontiers Media SA in Frontiers in Nutrition
- Vol. 11, 1398690
Screening and assessment of malnutrition in patients with liver cirrhosis
The development and advancement of malnutrition is associated not only with the progression of hepatic dysfunction, but also with cirrhosis-related complications. However, the prevalence of malnutrition reported in different studies varies widely due to differences in diagnostic methods and patient investigation settings. Therefore, we need to identify malnourished patients promptly and accurately. The purpose of this review was to compare the validity and reliability of nutritional screening tools and to select the most appropriate nutritional risk screening for patients with cirrhosis. We compared nutritional risk screening tools such as the Nutritional Risk Screening 2002 (NRS-2002), Malnutrition Universal Screening Tool (MUST), Royal Free Hospital-Nutritional Prioritizing Tool (RFH-NPT) and Liver Disease Undernutrition Screening Tool (LDUST). Royal Free Hospital-Nutritional Prioritizing Tool (RFH-NPT) is more feasible to screen cirrhotic patients for nutritional risk, and is highly reproducible, considering the impact of sodium and water retention; so it is practical to screen cirrhotic patients via RFH-NPT for nutritional risk, subsequently, to evaluate the nutritional status of patients with nutritional risk via the Global Leadership Initiative on Malnutrition (GLIM) diagnostic criteria. L3-SMI (third lumbar-skeletal muscle index) can accurately define sarcopenia in cirrhotic patients and also be used for clinical nutritional status assessment.
- 18 July 2024
- Published by Frontiers Media SA in Frontiers in Nutrition
- Vol. 11, 1398690
Open AccessScreening and assessment of malnutrition in patients with liver cirrhosis
The development and advancement of malnutrition is associated not only with the progression of hepatic dysfunction, but also with cirrhosis-related complications. However, the prevalence of malnutrition reported in different studies varies widely due to differences in diagnostic methods and patient investigation settings. Therefore, we need to identify malnourished patients promptly and accurately. The purpose of this review was to compare the validity and reliability of nutritional screening tools and to select the most appropriate nutritional risk screening for patients with cirrhosis. We compared nutritional risk screening tools such as the Nutritional Risk Screening 2002 (NRS-2002), Malnutrition Universal Screening Tool (MUST), Royal Free Hospital-Nutritional Prioritizing Tool (RFH-NPT) and Liver Disease Undernutrition Screening Tool (LDUST). Royal Free Hospital-Nutritional Prioritizing Tool (RFH-NPT) is more feasible to screen cirrhotic patients for nutritional risk, and is highly reproducible, considering the impact of sodium and water retention; so it is practical to screen cirrhotic patients via RFH-NPT for nutritional risk, subsequently, to evaluate the nutritional status of patients with nutritional risk via the Global Leadership Initiative on Malnutrition (GLIM) diagnostic criteria. L3-SMI (third lumbar-skeletal muscle index) can accurately define sarcopenia in cirrhotic patients and also be used for clinical nutritional status assessment.
- 2 December 2023
- Published by Elsevier in Experimental Cell Research
- Vol. 434 (1) , 113871
Upregulated Tβ4 expression in inflammatory bowel disease impairs the intestinal mucus barrier by inhibiting autophagy in mice
- 2 December 2023
- Published by Elsevier in Experimental Cell Research
- Vol. 434 (1) , 113871
Upregulated Tβ4 expression in inflammatory bowel disease impairs the intestinal mucus barrier by inhibiting autophagy in mice
- 28 November 2023
- Published by Wiley in Journal of Human Nutrition and Dietetics
- Vol. 37 (2) , 430-439
Nutritional screening and assessment tools for patients with cirrhosis based on the Global Leadership Initiative on Malnutrition criteria
Background: Malnutrition is highly prevalent and associated with complications and mortality in patients with cirrhosis.Methods: This was a prospective observational study. Patients with cirrhosis were screened using the Nutritional Risk Screening 2002, the Royal Free Hospital‐Nutritional Prioritizing Tool and the Skeletal Muscle Index. Then, the sensitivity, specificity, positive and negative predictive values, and consistency with the Global Leadership Initiative on Malnutrition criteria results were calculated. We also analysed the association between nutritional status and short‐term prognosis.Results: We enrolled 125 patients with cirrhosis, of whom 59.20% and 60.00% were malnourished based on the Global Leadership Initiative on Malnutrition criteria and Skeletal Muscle Index. Some 53.60% and 65.60%, respectively, were classified medium‐to‐high nutritional risk by Nutritional Risk Screening 2002 and the Royal Free Hospital‐Nutritional Prioritizing Tool. The Royal Free Hospital‐Nutritional Prioritizing Tool had the best predictive value, and it was more sensitive and had a better negative predictive value than the Nutritional Risk Screening 2002 Tool. The Skeletal Muscle Index also had good sensitivity and predictive value. The Royal Free Hospital‐Nutritional Prioritizing Tool, Skeletal Muscle Index and Global Leadership Initiative on Malnutrition criteria showed high concordance. The 3‐ and 6‐month mortality rates were significantly higher for patients with moderate‐to‐high nutritional risk or malnutrition, regardless of the tool.Conclusions: When assessing cirrhosis with the Global Leadership Initiative on Malnutrition criteria, the Royal Free Hospital‐Nutritional Prioritizing Tool is best for nutritional screening and the Skeletal Muscle Index is also a good nutritional assessment tool.
- 28 November 2023
- Published by Wiley in Journal of Human Nutrition and Dietetics
- Vol. 37 (2) , 430-439
Nutritional screening and assessment tools for patients with cirrhosis based on the Global Leadership Initiative on Malnutrition criteria
Background: Malnutrition is highly prevalent and associated with complications and mortality in patients with cirrhosis.Methods: This was a prospective observational study. Patients with cirrhosis were screened using the Nutritional Risk Screening 2002, the Royal Free Hospital‐Nutritional Prioritizing Tool and the Skeletal Muscle Index. Then, the sensitivity, specificity, positive and negative predictive values, and consistency with the Global Leadership Initiative on Malnutrition criteria results were calculated. We also analysed the association between nutritional status and short‐term prognosis.Results: We enrolled 125 patients with cirrhosis, of whom 59.20% and 60.00% were malnourished based on the Global Leadership Initiative on Malnutrition criteria and Skeletal Muscle Index. Some 53.60% and 65.60%, respectively, were classified medium‐to‐high nutritional risk by Nutritional Risk Screening 2002 and the Royal Free Hospital‐Nutritional Prioritizing Tool. The Royal Free Hospital‐Nutritional Prioritizing Tool had the best predictive value, and it was more sensitive and had a better negative predictive value than the Nutritional Risk Screening 2002 Tool. The Skeletal Muscle Index also had good sensitivity and predictive value. The Royal Free Hospital‐Nutritional Prioritizing Tool, Skeletal Muscle Index and Global Leadership Initiative on Malnutrition criteria showed high concordance. The 3‐ and 6‐month mortality rates were significantly higher for patients with moderate‐to‐high nutritional risk or malnutrition, regardless of the tool.Conclusions: When assessing cirrhosis with the Global Leadership Initiative on Malnutrition criteria, the Royal Free Hospital‐Nutritional Prioritizing Tool is best for nutritional screening and the Skeletal Muscle Index is also a good nutritional assessment tool.
- 1 March 2023
- Published by SAGE Publications in Genetic Testing and Molecular Biomarkers
- Vol. 27 (3) , 100-108
Meta-Analysis of the Association Between 5-Hydroxytryptamine Transporter Gene-Linked Polymorphic Region and Functional Dyspepsia and its Subtypes
Background: Association studies of variations in the 5-hydroxytryptamine (5-HT, serotonin) transporter gene-linked polymorphic region (5-HTTLPR) and functional dyspepsia (FD) have yielded contradictory results. Hence, we performed a meta-analysis to clarify inconsistencies between the 5-HTTLPR polymorphism with FD and it subtypes. Methods: We performed a literature search in PubMed, Embase, Web of Science, Cochrane Library, and CNKI, including articles published until March 2022. We calculated and pooled odds ratios (ORs) with their 95% confidence intervals (CIs) in Stata 15.0. Data extraction was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and Cochrane Handbook for Systematic Reviews of Interventions. Results: The meta-analysis included six studies, comprising 488 cases and 1513 healthy controls. We did not observe a significant association between the 5-HTTLPR polymorphism and FD in the overall population. In subgroup analyses, the 5-HTTLPR polymorphism was significantly associated with FD-subtype epigastric pain syndrome (EPS) (SS vs. LL+LS, OR = 0.620, 95% CI: 0.414–0.930; SS vs. LS, OR = 0.640, 95% CI: 0.417–0.980; S vs. L, OR = 0.655, 95% CI: 0.471–0.911). However, no association was observed with the other subtype, postprandial distress syndrome (PDS). Conclusion: While the 5-HTTLPR polymorphism had no relationship with FD overall, splitting the disease into its subtypes revealed a clear association with EPS.
- 1 March 2023
- Published by SAGE Publications in Genetic Testing and Molecular Biomarkers
- Vol. 27 (3) , 100-108
Meta-Analysis of the Association Between 5-Hydroxytryptamine Transporter Gene-Linked Polymorphic Region and Functional Dyspepsia and its Subtypes
Background: Association studies of variations in the 5-hydroxytryptamine (5-HT, serotonin) transporter gene-linked polymorphic region (5-HTTLPR) and functional dyspepsia (FD) have yielded contradictory results. Hence, we performed a meta-analysis to clarify inconsistencies between the 5-HTTLPR polymorphism with FD and it subtypes. Methods: We performed a literature search in PubMed, Embase, Web of Science, Cochrane Library, and CNKI, including articles published until March 2022. We calculated and pooled odds ratios (ORs) with their 95% confidence intervals (CIs) in Stata 15.0. Data extraction was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and Cochrane Handbook for Systematic Reviews of Interventions. Results: The meta-analysis included six studies, comprising 488 cases and 1513 healthy controls. We did not observe a significant association between the 5-HTTLPR polymorphism and FD in the overall population. In subgroup analyses, the 5-HTTLPR polymorphism was significantly associated with FD-subtype epigastric pain syndrome (EPS) (SS vs. LL+LS, OR = 0.620, 95% CI: 0.414–0.930; SS vs. LS, OR = 0.640, 95% CI: 0.417–0.980; S vs. L, OR = 0.655, 95% CI: 0.471–0.911). However, no association was observed with the other subtype, postprandial distress syndrome (PDS). Conclusion: While the 5-HTTLPR polymorphism had no relationship with FD overall, splitting the disease into its subtypes revealed a clear association with EPS.
- Open Access
- 29 December 2022
- Published by MDPI AG in Pharmaceuticals
- Vol. 16 (1) , 47
A Novel Mast Cell Stabilizer JM25-1 Rehabilitates Impaired Gut Barrier by Targeting the Corticotropin-Releasing Hormone Receptors
Mast cell (MC) plays a central role in intestinal permeability; however, few MC-targeting drugs are currently available for protection of the intestinal barrier in clinical practice. A nonfluorinated Lidocaine analog 2-diethylamino-N-2,5-dimethylphenyl acetamide (JM25-1) displays anti-allergic effect, but its impact on MC remains elusive. In this study, we explored whether JM25-1 has therapeutic potential on intestinal barrier defect through stabilizing MC. JM25-1 alleviated release of β-hexosaminidase and cytokine production of MC. The paracellular permeability was redressed by JM25-1 in intestinal epithelial cell monolayers co-cultured with activated MC. In vivo, JM25-1 diminished intestinal mucosal MC amount and cytokine production, especially downregulating the expression of CRHR1, accompanied by an increase of CRHR2. Protective effects appeared in JM25-1-treated stress rats with a recovery of weight and intestinal barrier integrity. Through network pharmacology analysis, JM25-1 showed a therapeutic possibility for irritable bowel syndrome (IBS) with predictive targeting on PI3K/AKT/mTOR signaling. As expected, JM25-1 reinforced p-PI3K, p-AKT, p-mTOR signaling in MC, while the mTOR inhibitor Rapamycin reversed the action of JM25-1 on the expression of CRHR1 and CRHR2. Moreover, JM25-1 successfully remedied intestinal defect and declined MC and CRHR1 expression in rat colon caused by colonic mucus of IBS patients. Our data implied that JM25-1 possessed therapeutic capacity against intestinal barrier defects by targeting the CRH receptors of MC through PI3K/AKT/mTOR signaling.
- 29 December 2022
- Published by MDPI AG in Pharmaceuticals
- Vol. 16 (1) , 47
Open AccessA Novel Mast Cell Stabilizer JM25-1 Rehabilitates Impaired Gut Barrier by Targeting the Corticotropin-Releasing Hormone Receptors
Mast cell (MC) plays a central role in intestinal permeability; however, few MC-targeting drugs are currently available for protection of the intestinal barrier in clinical practice. A nonfluorinated Lidocaine analog 2-diethylamino-N-2,5-dimethylphenyl acetamide (JM25-1) displays anti-allergic effect, but its impact on MC remains elusive. In this study, we explored whether JM25-1 has therapeutic potential on intestinal barrier defect through stabilizing MC. JM25-1 alleviated release of β-hexosaminidase and cytokine production of MC. The paracellular permeability was redressed by JM25-1 in intestinal epithelial cell monolayers co-cultured with activated MC. In vivo, JM25-1 diminished intestinal mucosal MC amount and cytokine production, especially downregulating the expression of CRHR1, accompanied by an increase of CRHR2. Protective effects appeared in JM25-1-treated stress rats with a recovery of weight and intestinal barrier integrity. Through network pharmacology analysis, JM25-1 showed a therapeutic possibility for irritable bowel syndrome (IBS) with predictive targeting on PI3K/AKT/mTOR signaling. As expected, JM25-1 reinforced p-PI3K, p-AKT, p-mTOR signaling in MC, while the mTOR inhibitor Rapamycin reversed the action of JM25-1 on the expression of CRHR1 and CRHR2. Moreover, JM25-1 successfully remedied intestinal defect and declined MC and CRHR1 expression in rat colon caused by colonic mucus of IBS patients. Our data implied that JM25-1 possessed therapeutic capacity against intestinal barrier defects by targeting the CRH receptors of MC through PI3K/AKT/mTOR signaling.